Emma Tallantyre

DMT management – where disease biology and treatment algorithms meet 1:26
DMT management – where disease biology and treatment algorithms meet
Emma Tallantyre • 23 Sep 2022
When should DMTs be stopped when treating MS? 2:11
When should DMTs be stopped when treating MS?
Emma Tallantyre • 23 Sep 2022
Progressive MS: discovering the new and repurposing the old 2:05
Progressive MS: discovering the new and repurposing the old
Emma Tallantyre • 23 Sep 2022
UK guidance on MS and the risk of infection 1:57
UK guidance on MS and the risk of infection
Emma Tallantyre • 23 Sep 2022
Long-term treatment with anti-CD20 mAbs – is it feasible? 2:50
Long-term treatment with anti-CD20 mAbs – is it feasible?
Emma Tallantyre • 23 Sep 2022
The content of VJNeurology is intended for healthcare professionals